In the past 5 years, important advances have been made in the scientific understanding and
clinical management of cholangiocarcinoma (CCA). The cellular immune landscape of CCA …

Background Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as
promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor …

Simple Summary Biliary tract cancers (BTCs) are rare tumours associated with poor
prognosis. In advanced-stage disease, two treatment lines are approved: gemcitabine …

Purpose: Genomic rearrangements can generate potent oncogenic drivers or disrupt tumor
suppressor genes. This study examines the landscape of fusions and rearrangements …

Cholangiocarcinomas (CCA) are a heterogeneous group of tumors that are classified as
intrahepatic, perihilar, or distal according to the anatomic location within the biliary tract …

Purpose: BRAF mutations are rare in biliary tract cancers (BTC), but are of interest given the
recent developments in targeted therapy for BTC. We investigated the clinical outcomes in a …

ALK, ROS1, and RET fusions and MET∆ ex14 variant associate with response to targeted
therapies in non‐small‐cell lung cancer (NSCLC). Technologies for fusion testing in tissue …

Fibroblast growth factor receptor (FGFR) alterations are present as oncogenic drivers and
bypass mechanisms in many forms of cancer. These alterations can include fusions …

Background Treatment patterns for intrahepatic cholangiocarcinoma (ICC) and extrahepatic
cholangiocarcinoma (ECC) differ, but limited studies exist comparing them. This study …

Biliary tract cancers (BTCs) represent a spectrum of malignancies associated with a dismal
prognosis. Recent genomic profiling studies have provided a deeper understanding of the …